Yuhan USA to participate at 2024 BIO International Convention in June
Yuhan USA to participate at 2024 BIO International Convention in June Yuhan USA, a subsidiary of Yuhan Corporation, will be participating in 2024 BIO International Convention on June 3-6 (San Diego, CA). Yuhan USA is looking for potential therapeutic assets with validated proof-of-concept data for in-licensing. The company’s R&D focus areas are Oncology (targeted therapy, […]
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients (biospectator.com)
Yuhan Corporation’s ‘IgE Trap; YH35324’ Surpasses ‘Xolair’ in Phase 1 Trials, Delivering Superior IgE Suppression in High IgE Patients YH35324 is an Fc fusion protein of the IgE series, ‘IgE Trap’, which is a form that fuses the extracellular domain of the IgE receptor (FcεR1) with a hybrid Fc. Its main mechanism of action is […]
‘Amivantamab’ and ‘Lazertinib’ Combination Treatment Shows Extended PFS as First-line of Therapy in NSCLC
Yuhan Corporation’s 3rd generation EGFR TKI, ‘Lazertinib’, has taken another step towards its global blockbuster aspirations.This achievement comes as a result of successful outcomes in the clinical trial named ‘MARIPOSA,’ in which Janssen evaluated the anti-cancer drug ‘Amivantamab’ in combination with ‘Lazertinib’ compared to AstraZeneca’s ‘Osimertinib’. According to industry reports on October 2nd, Janssen, a […]
Yuhan and Cyrus Therapeutics signed an agreement for Joint Research on Anti-Cancer Target Therapeutics
Yuhan announced that it has signed an MOU with Cyrus Therapeutics to develop a small molecule anti-cancer target therapy. Cyrus Therapeutics is a Korean biotechnology company with small molecule therapeutics and targeted proteolysis (TPD) technology that degrades protein and removes cancer cells. Through the agreement, the two companies plan to cooperate in the fields of […]
Yuhan Corporation Announces Free Supply of Its New Lung Cancer Drug “Lazertinib” Until Covered by Insurance through Expanded Access Program (EAP) in South Korea
Yuhan Corporation, a leading pharmaceutical company, has announced that it will provide its newly developed drug, “Lazertinib,” as a first-line treatment for free until it is covered by health insurance in South Korea. This initiative is in line with the company’s commitment to giving back to society, a value that was cherished by its late […]
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a preclinical HER2 tyrosine kinase inhibitor (TKI). The oral drug candidate, which Korea’s Yuhan is licensing from its compatriot J INTS BIO, is designed for use in non-small cell lung cancer […]
Business Development Manager Position Opening
Yuhan USA Corporation– 유한양행 미국 법인 Work locations: San Diego, CA or Boston, MA Employee type: Full-time Visa Sponsorship available: No Contact Information: info@yuhan-usa.com 유한USA는 96년의 전통을 가진 한국 최대 제약회사 중 하나인 유한양행의 미국 법인으로 유한양행이 글로벌 제약사로 발돋움 하기 위한 세계화 전략의 전초기지로서 사업 개발 및 신약 개발 협업의 기회를 함께할 인재를 찾고 […]
Yuhan Corporation acquires Progen, a multi-target antibody company based in South Korea for total of $23M investment
Yuhan Corporation announced on April 5, 2023, that it has signed an investment agreement to secure the largest shareholder stake in Progen Inc., a company with multi-target antibody-based platform technology. Progen Inc. is a biotechnology company with 25 years of experience in platform-based drug discovery and development. The company has a platform technology for immunoglobulin […]
Yuhan Corporation confirms efficacy of Lazertinib, a new drug for NSCLC in Phase 3 trial
The top line results for the phase 3 clinical trial of the 3rd generation EGFR TKI ‘Lazertinib’ being developed by Yuhan Corporation have been announced. The results confirmed the efficacy of Lazertinib as a first-line treatment and Yuhan Corporation plans to submit an application for approval to expand indications in South Korea in Q1 of […]
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
Processa Pharmaceuticals announced that positive gastric emptying results from its PCS12852 Phase 2A Proof-of-Concept trial in patients with moderate to severe gastroparesis. PCS12852 is a novel, potent, and highly selective 5-hydroxytryptamine-4 (5-HT4) receptor agonist, originally developed by Yuhan Corporation in South Korea, and exclusively licensed to Processa Pharmaceuticals in August 2020 (https://bit.ly/30iKnMR). This Phase 2A […]